ClinicalTrials.gg
Active, not recruitingNCT04961840Updated Oct 13, 2026

A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

An observational study in Constipation and Pregnancy, sponsored by Takeda. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Takeda · Observational

How we know

Updated Oct 13, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Constipation by Takeda — none open to participants now, 2 under way, none of them phase 3. Constipation · Takeda.

Started
2022
the only one that year
Observational
2 of 29
none open now
Registered
29th of 29
by date

Among the 29 studies in Constipation by Takeda, this one is the only one that started in 2022, is one of 2 observational ones, and was the 29th registered.

Constipation

1,048 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 29 studies in Constipation by Takeda is open now. The open studies under Constipation, anywhere →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 44 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Constipation by Takeda as a file.
02

Study summary

This study will collect information on pregnant women diagnosed with constipation from the two large health care insurance claims records.

It will include the following groups:

  • Those who took prucalopride.
  • Those who took other medicines for constipation.
  • Those who did not take any prescription medicines for constipation.

The main aim of the study is to find out whether the medicine prucalopride, which is used to treat constipation, is safe for use during pregnancy and to look at whether taking prucalopride at certain times during pregnancy is associated to a higher chance of specific health problems for the mother or baby.

The study uses two large existing healthcare insurance databases for collecting information. Participants are not enrolled, treated, or required to visit the doctor during this study.

03

Conditions studied

  • Constipation
  • Pregnancy

Browse trials for

Keywords

  • Prucalopride
  • infant outcomes
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will include pregnancy women with constipation including those with constipation predominant irritable bowel syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 18 to 44 years with constipation.
  • Maternal coverage by health care and prescriptions insurance during eligibility period:

    a) To study pregnancy outcomes (live births, spontaneous abortions, terminations, or stillbirths): 90 days prior to the LMP until end of pregnancy; and b) to study malformations, perinatal, and infant outcomes: 90 days to LMP until 30 days post-delivery.

  • For infant outcomes, the cohort will be restricted to pregnancies with linked offspring.
  • For major malformations, only pregnancies with livebirths will be included, since information regarding the pathology results from a pregnancy loss or the indication for termination is rarely recorded. In addition, infants are required to have full insurance coverage from delivery to at least 90 days after the delivery, unless the infant died prior to the end of the 90 days, in which case a shorter eligibility period until death is permitted.
  • For the analyses of pregnancy losses, the cohort also includes pregnancies ending in spontaneous abortion, terminations, stillbirth and any livebirth (linked or unlinked to a delivery).

Exclusion criteria

Exclusion Criteria:

  • Women with opioids dispensed in the 90 days prior to LMP or during the first trimester (to exclude potential opioid-induced constipation).
  • Women with inflammatory bowel diseases (IBDs) identified based on ICD codes recorded in the 90 days prior to LMP or during the first trimester (because it is a ).
  • For major malformations, pregnancies with outpatient exposure to definite teratogens including warfarin, valproate, antineoplastic agents, colchicine, testosterone, radioiodine, isotretinoin, misoprostol, and thalidomide from LMP through LMP plus 90 days.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1: Pregnant Women Exposed to Prucalopride

    Pregnant women with clinically diagnosis of constipation who have been exposed to prucalopride during pregnancy will be observed.

    Other: No Intervention

  • Cohort 2: Pregnant Women Not Exposed to Prucalopride

    Pregnant women with clinical diagnosis of constipation who have been exposed to other constipation drugs and not prucalopride during pregnancy will be observed.

    Other: No Intervention

  • Cohort 3: Untreated Pregnant Women

    Pregnant women with clinical diagnosis of constipation with no recorded prescription dispensed for any constipation drugs during pregnancy will be observed.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    This is a non-interventional study.

06

What researchers measure

Primary outcomes

  1. Percentage of Infants With Major Congenital Malformations

    A major congenital malformation is defined as a structural abnormality with surgical, medical, or cosmetic importance. Major malformations will be sorted and grouped according to the International Classification of Diseases 10th Revision (ICD-10). Percentage of infants with major congenital malformations after birth will be reported.

    Time frame: From delivery up to 90 days post-delivery

Secondary outcomes

  1. Percentage of Participants With Spontaneous Abortions

    Spontaneous abortions will be defined as spontaneous losses before 20 weeks of gestation. Percentage of participants with spontaneous abortion will be reported.

    Time frame: 90 days prior to the Last menstrual period (LMP) until end of pregnancy

  2. Percentage of Participants With Terminations (Discontinuation of Pregnancy)

    Percentage of participants with discontinuation of pregnancy through medication or surgical procedures will be reported.

    Time frame: 90 days prior to the LMP until end of pregnancy

  3. Percentage of Participants With Stillbirths

    Stillbirths will be defined as in utero fetal deaths at or after 20 weeks of gestation. Percentage of participants with stillbirths will be reported.

    Time frame: 90 days prior to the LMP until end of pregnancy

  4. Percentage of Participants With Preterm Delivery

    Preterm delivery is defined as a live birth occurring at less than (\<) 37 gestational weeks.

    Time frame: From Delivery to 30 days post-delivery

  5. Percentage of Infants With Small for Gestational Age (SGA)

    SGA will be defined as weight at birth of full and preterm live-born infants in \<10th percentile. Percentage of infants with SGA will be reported.

    Time frame: From Delivery to 30 days post-delivery

  6. Percentage of Infants With Neonatal Intensive Care Unit (NICU) Admission

    Percentage of infants admitted to NICU in relation to early and late pregnancy. exposure to prucalopride will be reported.

    Time frame: From Delivery to 30 days post-delivery

  7. Percentage of Infants With Hospitalizations

    Percentage of infants With Hospitalizations during the first year of life in relation to prenatal exposure to prucalopride will be reported.

    Time frame: From Delivery to 365 days post-delivery

  8. Percentage of Infants With Poor Growth and Developmental Delays or Disorders

    Percentage of infants With Poor Growth and developmental delays or disorders during the first year of life in relation to prenatal exposure to prucalopride will be reported.

    Time frame: From Delivery to 365 days post-delivery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2022 (actual). Primary completion is estimated for Jun 2027, 65 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2021
First posted
Jul 14, 2021
StartActual
Jan 1, 2022
Primary completionEst.
Jun 30, 2027was Dec 2026
CompletionEst.
Jun 30, 2027was Dec 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Jun 30, 2027
Oct 13, 2026
Study completion
Dec 31, 2026→Jun 30, 2027
Oct 13, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedTo study pregnancy outcomes (live births, spontaneous abortions, terminations, or stillbirths): 90 days prior to the LMP until end of pregnancy; and b) to study malformations, perinatal, and infant outcomes: 90 days to LMP until 30 days post-delivery.
  • EditedFor major malformations, only pregnancies with livebirths will be included, since information regarding the pathologicalpathology results from a pregnancy loss or the indication for termination is rarely recorded. In addition, infants are required to have full insurance coverage from delivery to at least 90 days after the delivery, unless the infant died prior to the end of the 90 days, in which case a shorter eligibility period until death is permitted.
Exclusion criteria
  • EditedWomen with opioids dispensed in the 3 months90 days prior to LMP or during the first trimester (to exclude potential opioid-induced constipation) and women with inflammatory bowel diseases (IBD) (because IBD is a contraindication).
  • RemovedFor major malformations, the cohort excludes pregnancies with a chromosomal abnormality based on at least one inpatient or outpatient ICD-9 code for 758.xx,759.81-759.83, or 655.1x within 90 days after delivery in the infant and/or maternal claims.
  • AddedWomen with inflammatory bowel diseases (IBDs) identified based on ICD codes recorded in the 90 days prior to LMP or during the first trimester (because it is a contraindication).
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Dec 31, 2026→Jun 30, 2027
    Study completion Dec 31, 2026→Jun 30, 2027
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedTo study pregnancy outcomes (live births, spontaneous abortions, terminations, or stillbirths): 90 days prior to the LMP until end of pregnancy; and b) to study malformations, perinatal, and infant outcomes: 90 days to LMP until 30 days post-delivery.
    • EditedFor major malformations, only pregnancies with livebirths will be included, since information regarding the pathologicalpathology results from a pregnancy loss or the indication for termination is rarely recorded. In addition, infants are required to have full insurance coverage from delivery to at least 90 days after the delivery, unless the infant died prior to the end of the 90 days, in which case a shorter eligibility period until death is permitted.
    Exclusion criteria
    • EditedWomen with opioids dispensed in the 3 months90 days prior to LMP or during the first trimester (to exclude potential opioid-induced constipation) and women with inflammatory bowel diseases (IBD) (because IBD is a contraindication).
    • RemovedFor major malformations, the cohort excludes pregnancies with a chromosomal abnormality based on at least one inpatient or outpatient ICD-9 code for 758.xx,759.81-759.83, or 655.1x within 90 days after delivery in the infant and/or maternal claims.
    • AddedWomen with inflammatory bowel diseases (IBDs) identified based on ICD codes recorded in the 90 days prior to LMP or during the first trimester (because it is a contraindication).
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04961840
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 14, 2021
Start date
Jan 1, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion